Related references
Note: Only part of the references are listed.Assessing CAR T-Cell Therapy Response Using Genome-Wide Sequencing of Cell-Free DNA in Patients With B-Cell Lymphomas
Aaron M. Goodman et al.
TRANSPLANTATION AND CELLULAR THERAPY (2022)
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy
Mark Jesus M. Magbanua et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Laura Keller et al.
BRITISH JOURNAL OF CANCER (2021)
Trials of Immunotherapy in Triple Negative Breast Cancer
Ozge Gumusay et al.
CURRENT BREAST CANCER REPORTS (2021)
The Use of Serial Circulating Tumor DNA to Detect Resistance Alterations in Progressive Metastatic Breast Cancer
Saya Jacob et al.
CLINICAL CANCER RESEARCH (2021)
Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival
M. J. M. Magbanua et al.
ANNALS OF ONCOLOGY (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial
Eric P. Winer et al.
LANCET ONCOLOGY (2021)
A Review of Circulating Tumour Cell Enrichment Technologies
Amelia J. Rushton et al.
CANCERS (2021)
Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2021)
Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial
Jose M. Perez-Garcia et al.
EUROPEAN JOURNAL OF CANCER (2021)
Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
Mark Jesus M. Magbanua et al.
NPJ BREAST CANCER (2021)
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
L. A. Emens et al.
ANNALS OF ONCOLOGY (2021)
KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
J. Cortes et al.
ANNALS OF ONCOLOGY (2021)
KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab D chemotherapy vs. placebo D chemotherapy, followed by adjuvant pembrolizumab vs. placebo for earlystage TNBC
P. Schmid et al.
ANNALS OF ONCOLOGY (2021)
Programmed Cell Death Ligand 1-Expressing Circulating Tumor Cells: A New Prognostic Biomarker in Non-Small Cell Lung Cancer
Lea Sinoquet et al.
CLINICAL CHEMISTRY (2021)
Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).
Sibylle Loibl et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Genome-wide Sequencing of Cell-free DNA Enables Detection of Copy-number Alterations in Patients with Cancer Where Tissue Biopsy is Not Feasible
Taylor J. Jensen et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Signed in Blood: Circulating Tumor DNA in Cancer Diagnosis, Treatment and Screening
Jacob J. Adashek et al.
CANCERS (2021)
Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy
Daniel Araujo et al.
JNCI CANCER SPECTRUM (2021)
Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy
Daniel Araujo et al.
JNCI CANCER SPECTRUM (2021)
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
Peter Schmid et al.
LANCET ONCOLOGY (2020)
Prevalence and mutational determinants of high tumor mutation burden in breast cancer
R. Barroso-Sousa et al.
ANNALS OF ONCOLOGY (2020)
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice
Paula Gonzalez-Ericsson et al.
JOURNAL OF PATHOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study
Muhammad A. Khattak et al.
ONCOLOGIST (2020)
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial
Rita Nanda et al.
JAMA ONCOLOGY (2020)
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer
Ami N. Shah et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Tissue-Plasma TMB Comparison and Plasma TMB Monitoring in Patients With Metastatic Non-small Cell Lung Cancer Receiving Immune Checkpoint Inhibitors
Alex Friedlaender et al.
FRONTIERS IN ONCOLOGY (2020)
Comment on 'Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA' by M. C. Liu et al.
W. C. Taylor
ANNALS OF ONCOLOGY (2020)
Nucleosome positioning sequence patterns as packing or regulatory
Erinija Pranckeviciene et al.
PLOS COMPUTATIONAL BIOLOGY (2020)
Prognostic impact of ESR1 mutations in ER+ HER2- MBC patients prior treated with first line AI and palbociclib: An exploratory analysis of the PADA-1 trial.
Francois Clement Bidard et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer
William Jacot et al.
CLINICAL CHEMISTRY (2020)
Landscape of circulating tumour DNA in metastatic breast cancer
Andrew A. Davis et al.
EBIOMEDICINE (2020)
IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab plus nab-paclitaxel vs placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
L. A. Emens et al.
ANNALS OF ONCOLOGY (2020)
Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first- line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
D. W. Miles et al.
ANNALS OF ONCOLOGY (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
Senescence, Necrosis, and Apoptosis Govern Circulating Cell-free DNA Release Kinetics
Ariana Rostami et al.
CELL REPORTS (2020)
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
Elizabeth A. Mittendorf et al.
LANCET (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
Leisha A Emens et al.
LANCET ONCOLOGY (2020)
Circulating Tumor Cells: From the Laboratory to the Cancer Clinic
Ruchi Agashe et al.
CANCERS (2020)
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortes et al.
LANCET (2020)
Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer A Systematic Review and Meta-analysis
Carolyn Cullinane et al.
JAMA NETWORK OPEN (2020)
Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab
Scott V. Bratman et al.
NATURE CANCER (2020)
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study
Luca Gianni et al.
CANCER RESEARCH (2020)
Circulating tumor DNA and liquid biopsy in oncology
David W. Cescon et al.
NATURE CANCER (2020)
Evaluation of PD-L1 expression on circulating tumor cells (CTCs) in patients with advanced urothelial carcinoma (UC)
Sonja Bergmann et al.
ONCOIMMUNOLOGY (2020)
Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial
Sherene Loi et al.
LANCET ONCOLOGY (2019)
Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies
Rebecca Shatsky et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Molecular Interactions of Antibody Drugs Targeting PD-1, PD-L1, and CTLA-4 in Immuno-Oncology
Hyun Tae Lee et al.
MOLECULES (2019)
Liquid biopsy and minimal residual disease - latest advances and implications for cure
Klaus Pantel et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer
Young Kwang Chae et al.
ONCOLOGIST (2019)
A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
S. Loibl et al.
ANNALS OF ONCOLOGY (2019)
Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence
Raoul Charles Coombes et al.
CLINICAL CANCER RESEARCH (2019)
Genome-wide cell-free DNA fragmentation in patients with cancer
Stephen Cristiano et al.
NATURE (2019)
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer
Fabrice Andre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?
P. Hofman et al.
ANNALS OF ONCOLOGY (2019)
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer
Isaac Garcia-Murillas et al.
JAMA ONCOLOGY (2019)
1191OPhase II study of olaparib (O) and durvalumab (D) (MEDIOLA): Updated results in patients (pts) with germline BRCA-mutated (gBRCAm) metastatic breast cancer (MBC)
S Domchek et al.
ANNALS OF ONCOLOGY (2019)
LBA21KEYNOTE-119: Phase III study of pembrolizumab (pembro) versus single-agent chemotherapy (chemo) for metastatic triple negative breast cancer (mTNBC)
J Cortés et al.
ANNALS OF ONCOLOGY (2019)
Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer A Phase 1 Study
Leisha A. Emens et al.
JAMA ONCOLOGY (2019)
Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection
Peter Ulz et al.
NATURE COMMUNICATIONS (2019)
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
S. Adams et al.
ANNALS OF ONCOLOGY (2019)
Genome-Wide Sequencing of Cell-Free DNA Identifies Copy-Number Alterations That Can Be Used for Monitoring Response to Immunotherapy in Cancer Patients
Taylor J. Jensen et al.
MOLECULAR CANCER THERAPEUTICS (2019)
Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays
Ping Qiu et al.
SCIENTIFIC REPORTS (2019)
Concordance of Genomic Variants in Matched Primary Breast Cancer, Metastatic Tumor, and Circulating Tumor DNA: The MIRROR Study
Fernando Moreno et al.
JCO PRECISION ONCOLOGY (2019)
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Laura Keller et al.
NATURE REVIEWS CANCER (2019)
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Andrea Nicolini et al.
SEMINARS IN CANCER BIOLOGY (2018)
The emerging world of breast cancer immunotherapy
Mark R. Nathan et al.
BREAST (2018)
Phase 2 study and correlative analyses of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic, triple-negative breast cancer
Daniel G. Stover et al.
CANCER RESEARCH (2018)
Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer
Hope S. Rugo et al.
CLINICAL CANCER RESEARCH (2018)
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
Francois-Clement Bidard et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
Nicolas Guibert et al.
LUNG CANCER (2018)
Adverse Events Associated with Immune Checkpoint Blockade
Kenar D. Jhaveri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
Francois-Clement Bidard et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Prevalence of Clonal Hematopoiesis Mutations in Tumor-Only Clinical Genomic Profiling of Solid Tumors
Ryan N. Ptashkin et al.
JAMA ONCOLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Markus Mayrhofer et al.
GENOME MEDICINE (2018)
The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer
Arutha Kulasinghe et al.
CANCER MEDICINE (2018)
Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy
Francesca Fenizia et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Tumor mutation burden (TMB), microsatellite instability (MSI), and chromosomal instability (CIN) analysis using low pass whole genome sequencing of single circulating tumor cell (CTC)
Angel Rodriguez et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer
M. Ilie et al.
ANNALS OF ONCOLOGY (2018)
Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed
Wendie D. den Brok et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Circulating tumor cells: clinical validity and utility
Luc Cabel et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2017)
Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer
Young Kwang Chae et al.
MOLECULAR CANCER THERAPEUTICS (2017)
A CD47-associated super-enhancer links pro-inflammatory signalling to CD47 upregulation in breast cancer
Paola A. Betancur et al.
NATURE COMMUNICATIONS (2017)
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis
Minghui Zhang et al.
ONCOTARGET (2017)
Sensitive detection of PD-L1 expression on circulating epithelial tumor cells (CETCs) could be a potential biomarker to select patients for treatment with PD-1/PD-L1 inhibitors in early and metastatic solid tumors
Dorothea Sonja Schott et al.
ONCOTARGET (2017)
Whole exome sequencing for determination of tumor mutation load in liquid biopsy from advanced cancer patients
Florence Koeppel et al.
PLOS ONE (2017)
Tumor Cell-Free DNA Copy Number Instability Predicts Therapeutic Response to Immunotherapy
Glen J. Weiss et al.
CLINICAL CANCER RESEARCH (2017)
Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma
A. Strati et al.
ANNALS OF ONCOLOGY (2017)
Liquid Biopsies, What We Do Not Know (Yet)
Alberto Bardelli et al.
CANCER CELL (2017)
Clinical relevance of host immunity in breast cancer: from TILs to the clinic
Peter Savas et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Origins, structures, and functions of circulating DNA in oncology
A. R. Thierry et al.
CANCER AND METASTASIS REVIEWS (2016)
Cell-free DNA Comprises an In Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin
Matthew W. Snyder et al.
CELL (2016)
Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Catherine Alix-Panabieres et al.
CANCER DISCOVERY (2016)
Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab
Camille Hua et al.
JAMA DERMATOLOGY (2016)
Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes A Systematic Review
Sasha E. Stanton et al.
JAMA ONCOLOGY (2016)
Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor Nivolumab
Chiara Nicolazzo et al.
SCIENTIFIC REPORTS (2016)
Circulating Tumor Cells and Circulating Tumor DNA: Challenges and Opportunities on the Path to Clinical Utility
Michail Ignatiadis et al.
CLINICAL CANCER RESEARCH (2015)
Predictive and prognostic cancer biomarkers revisited
Kenneth P. H. Pritzker
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2015)
Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
Hansje-Eva Teulings et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Pseudoprogression and Immune-Related Response in Solid Tumors
Victoria L. Chiou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Frequent expression of PD-L1 on circulating breast cancer cells
Martine Mazel et al.
MOLECULAR ONCOLOGY (2015)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer
Isaac Garcia-Murillas et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial
Judy C. Boughey et al.
ANNALS OF SURGERY (2014)
Current and future role of neoadjuvant therapy for breast cancer
Michael Untch et al.
BREAST (2014)
Detection of circulating tumor DNA in early and late stage human malignancies
Chetan Bettegowda et al.
CANCER RESEARCH (2014)
Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients
Brigitte Rack et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
Francois-Clement Bidard et al.
LANCET ONCOLOGY (2014)
PD-L1 Expression in Triple-Negative Breast Cancer
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Sarah-Jane Dawson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer
Rin Yamaguchi et al.
HUMAN PATHOLOGY (2012)
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
Gunter von Minckwitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Siddhartha Jaiswal et al.
CELL (2009)
Basal-like breast cancer defined by five biomarkers has superior prognostic value then triple-negative phenotype
Maggie C. U. Cheang et al.
CLINICAL CANCER RESEARCH (2008)
Quantification and phenotypic characterization of circulating tumor cells for monitoring response to a preventive HER2/neu vaccine-based immunotherapy for breast cancer:: A pilot study
Alexander Stojadinovic et al.
ANNALS OF SURGICAL ONCOLOGY (2007)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer
M Cristofanilli et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
